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Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more susceptible to viral, bacterial,
andfungalinfectionsbecauseoftheirmechanismofaction.Theynotonlyincreasetheriskofnewinfectionsbutalsoactalteringthe
naturalcourseofpreexistinginfections.Whilenumerousdataregardingthereactivationoftuberculosisinfectionareavailableinthe
literature, poor information about the risk of reactivation or exacerbation of hepatitis viruses B and C infections during treatment
with biologics has been reported. Furthermore, reported series with biological therapy included short periods of followup, and
therefore, they are not adequate to verify the risk of reactivation in the long-term treatment. Our study evaluated patients with a
historyofhepatitisBandpsoriaticarthritistreatedwithadalimumabandmonitoreduptosixyears.Duringtheobservationperiod,
treatment was effective and well tolerated in all patients, and liver function tests and viral load levels remained unchanged.
1. Introduction
Immunosuppressive agents used in psoriatic arthritis (PsA)
mighthaveaneffectonthenaturalcourseofcoexistinginfec-
tious diseases or new developed infections. An association
between the use of antitumor necrosis factor (TNF) and an
increased risk of severe bacterial infections or reactivation
of tuberculosis has been reported [1]. Long-term safety and
efficacy of anti-TNF agents in patients with chronic hepatitis
B or hepatitis C are not known [1]. There is increasing
evidence demonstrating elevated serum levels of TNF-𝗼 in
hepatitis-C-virus-(HCV-) infected patients compared with
healthy controls, and a correlation exists between elevated
TNF-𝗼 levels and serum alanine aminotransferase (ALT)
levels. These findings suggest that TNF-𝗼 may be involved in
the pathogenesis of hepatocyte destruction in chronic HCV
infection.Casereportsandasmallprospectivestudyindicate
thatanti-TNFtherapymaybesafe,andevenbeneficial,touse
in chronic HCV [2–6]. In contrast to HCV, TNF-𝗼 may play
a role in clearing and controlling hepatitis B virus (HBV).
Elevated levels of TNF-𝗼 a r eo b s e r v e di nb o t ht h es e r u m
and hepatocytes of patients with chronic HBV, and TNF-𝗼
expression is markedly upregulated in acute-on-chronic liver
failure in chronically HBV-infected patients [7, 8].
TNF-𝗼 is secreted by HBV-specific cytotoxic T lympho-
cytes (CTL) and seems to be synergizing with interferons in
suppressing viral replication [9]. Animal studies show that
TNF-𝗼 knockout mice have defects in the proliferative capa-
city of the HBV-specific CTL, suggesting that TNF-𝗼 may
play a role in clearing or controlling HBV [10]. Therefore,
inactivation of TNF-𝗼 could theoretically lead to enhanced
viral replication and reactivate or worsen the disease [11].
The risk of HBV reactivation appears to be linked both
to the phase of immunosuppression and to that of immune2 Clinical and Developmental Immunology
reconstitution. The risk of clinical events is mainly observed
in active carriers of HBV but can also develop in the occult
condition of infection which has been widely described in
the literature in the last decade (Table 1)[ 12]. For patients
with a known history of HBV who are HBsAg negative,
the risk of reactivation appears to be significantly lower, but
cannot be totally ruled out [13]. In the rheumatologic field,
reports regarding the reactivation of HBV during the course
of hydroxychloroquine, azathioprine, methotrexate, and
other conventional DMARDs are episodic [14]. Safety and
efficacy of anti-TNF agents in chronic hepatitis B are not
known,anddataavailableonreactivationoftheseviralinfec-
tions are conflicting [15].
2. Patients and Methods
We enrolled eight patients, four females and four males, aged
between 35 and 70 years, all suffering from PsA resistant
and/or intolerant to conventional DMARDs, referred to our
outpatients’ clinics between 2006 and 2010. The average
valuesofDAS28andPASIbeforestartingbiologicagentwere
respectively, 6.49 ± 0.54 and 14 ± 15.62.N o n eo ft h ep a t i e n t s
was aware of previous HBV infection nor of the period of
contagion. All patients were HCV negative.
Before starting immunosuppressive therapy, serological
m a r k e r so fH B Vw e r ee v a l u a t e di ne a c hp a t i e n t .Th ec a s e si n
this study included 1 case of an inactive HBsAg carrier and 7
cases of HBcAb-positive cases, 6 of which can be considered
as “past HBV infection.” All patients were negative for
HBeAg. Patients’ characteristics at baseline are shown in
Table 2.
Allpatientsstartedthetreatmentwiththeanti-TNFadali-
mumab(Humira,AbbottLaboratories);onlytheinactivecar-
rier was subjected to prophylactic therapy with lamivudine
100mg/day [16] ,w h i c hw a ss t a r t e d1m o n t hb e f o r es t a r t i n g
a n t i - T N F .A d a l i m u m a bw a sa d m i n i s t e r e da tt h es t a n d a r d
dose of 40mg every 2 weeks.
3. Results
D u r i n gt h et r e a t m e n tpe r i od ,w eh a v ec a r r i e do u tt h eev a l u a -
tion of HBV markers and liver function initially after three
months, and thereafter every six months; in all patients,
t h r o u g h o u tt h et r e a t m e n tpe r i od ,t h eH B Vm a r k e r sa n dl i v e r
function values remained stable. After the first six months
each patient achieved clinical remission of both skin lesions
and joint symptoms defined as DAS28 < 2.6 and 75% im-
provement in the PASI score.
The inactive carrier achieved clinical remission after the
first few months of therapy with adalimumab; treatment was
continued for 24 months and then stopped for the potential
risk of reactivationof the viral disease and also because of the
stable regression of psoriatic disease. Lamivudine was con-
tinued for further three months after the suspension of adal-
imumab.
Table 1: Relevant virologic categories of hepatitis B infection.
Markers Active carrier Inactive carrier Occult carrier
HBsAg + + −
HBeAg +/−− −
HBV-DNA >2000IU/mL <2000IU/mL −
HBcAb IgM +/−− −
HBcAb + + +
HBeAb +/− +/− +/−
HBsAb −− +/−
4. Discussion
Todate,onlyfewstudiesregardingtheuse,efficacy,andtoler-
ability of anti-TNF in psoriaticdisease patients with previous
HBV infection have been carried out and included a small
number of patients (Table 3)[ 17–20].
Inclinicalpractice,theguidelinesfortheuseofbiological
drugs in PsA published in 2005 are usually considered [21].
According to these, HBV infection is considered a relative
contraindication [21]. Therefore, the treatment is considered
when absolutely necessary after evaluation of the risk of viral
reactivation.
In fact, during the treatment with anti-TNF agents, sev-
eral cases of transient viral reactivation, regressed with anti-
viral therapy, and rare cases of fulminant hepatitis have been
reported,particularlyinpatientstreatedwithinfliximab[22].
Itseemsthattheriskofviralreactivationduringimmuno-
suppressivetherapychangesaccordingtopatients’serological
category [23–27].
We can distinguish active carriers (HBsAg pos, HBV-
DNA > 2000IU/mL), inactive carriers (HBsAg pos, HBV-
DNA < 2000IU/mL), occult carriers (HBsAg neg, HBcAb
pos), and patients with past HBV infection (HBsAg neg,
HBcAb pos, and HBsAb pos).
The risk of reactivation appears to be greater in HBsAg-
positivepatientsandlower,notexceeding5%,inandHBsAg-
negative HBcAb-positive patients (carriers or not of HBsAb)
[19, 28].
Data in the literature are still conflicting. A report of 266
patients showed a higher incidence of abnormal liver func-
tion in 88 occult carriers treated with etanercept, infliximabs
or adalimumab, compared with the control group [29].
Data regarding the appropriateness of biological treat-
ments in patients with a history of hepatitis are contrasting,
depending not only on the small number of patients treated
b u te s p e c i a l l yo nt h es h o r tp e r i o do ft r e a t m e n tr e p o r t e d .
Our study represents a series of patients suffering from
P s Aw i thah i s t o ryo fh e pa ti ti sBtr ea t edw i tha d al i m u m a bu p
to six years. Since 2006, we followed 8 patients observing the
serological pattern, liver function, and viral load throughout
the treatment period.
Patients’ serological pattern was not uniform: a patient
was inactive carrier; other patients were occult carriers
(among these 6 cases could be considered as past HBV infec-
tion).Inallpatients,theviralloadwasnegative,andliverfun-
ction was normal. In accordance with the guidelines of the
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Table 2: Patient’s baseline characteristics.
Pt Sex Age
PsA
duration
(years)
DAS28 PASI HBV
DNA
HBsAg HBsAb HBcAb HCV Ab ALT Drug Class Year of starting ADA
1 M5 5 6 6.1 0 Neg Neg Pos Pos Neg N ADA OC
(PI)
2006
2 M7 0 3 6.3 0 Neg Pos Neg Pos Neg N ADA IC 2007
3 F5 5 1 5.5 26.2 Neg Neg Pos Pos Neg N ADA OC
(PI)
2007
4 F6 7 5 7.0 31.8 Neg Neg Neg Pos Neg N ADA OC 2008
5 M3 7 1 6.8 14.2 Neg Neg Pos Pos Neg N ADA OC
(PI)
2008
6 F4 7 4 7.2 0 Neg Neg Pos Pos Neg N ADA OC
(PI)
2009
7 M6 2 2 6.4 2.8 Neg Neg Pos Pos Neg N ADA OC
(PI)
2010
8 F3 5 2 6.6 37.0 Neg Neg Pos Pos Neg N ADA OC
(PI)
2010
Pt: patient; Class: classification; ADA: adalimumab; N: normal; OC: occult carrier; PI: past infection; IC: inactive carrier.
Table 3: Previous reports about anti-TNF use in HBV active/inactive/occult carriers with psoriatic disease.
Study Study
type
PsA/Pso
patients
Patients’
categories Premedication Anti-TNF Followup
period HBV reactivation
Cassano et al.
2011 [17] R 34 PsA
28 PsO OC No
44 ETA
10 ADA
8I F X
About
4y e a r s
Reappearance of HBsAg without
detectable HBV-DNA in 1 patient
Prignano et al.
2011 [18] R 11 PsO OC No ETA 7.8 months No viral reactivation
Cho et al. 2012
[19] R 5P s A
2P s O
2I C
5A C
1p a t i e n t sh a d
lamivudine
and then
entecavir
1A D A
6E T A
26.6
months
(range
14–45)
3 patients had HBV reactivation
Fotiadou et al.
2011 [20] R 7 PsO IC Lamivudine
3A D A
3E T A
1I F X
6–24
months
1p a t i e n t
receiving IFX had increase of viral load up
to 600IU/mL
Psa: psoriatic arthritis; PsO: psoriasis; R: retrospective; OC: occult carrier; IC: inactive carrier; AC: active carriers; ADA: adalimumab; ETA: etanercept; IFX:
infliximab.
patient was subjected to prophylaxis with lamivudine, which
began before immunosuppression and continued for three
months after therapy suspension [25].
Prophylactic treatment with lamivudine should start 2–4
weeks before the immunosuppressive therapy and continue
for 6–12 months after the suspension of the same. In these
patients, the assessment of transaminases and viral load is
very important because the increase of the viral load over
10 times is associated to the possible development of resis-
tance to lamivudine. Unlike cancer patients, who are treated
with immunosuppressive drugs for short periods, rheumatic
patients have to be treated for longer period, and this makes
the role of antiviral prophylaxis still debated, as it is not clear
what is the optimal period of treatment to avoid possible
resistance induction. However, lamivudine seems to be effec-
tive in patients treated with anti-TNF, although the control
groups are needed to confirm this finding.
The7occultcarriersenrolledhadlowviralload,andthey
did not receive any prophylactic drug as previously reported
[11, 30]. To date, only the inactive carrier, which obtained
stable clinical remission, discontinued treatment after
24 months, for the potential risk of viral disease reactivation.
The other 7 patients are still in treatment and show no signs
of viral reactivation or flare of joint or skin disease.
In our study, adalimumab administered for a long period
has been proved effective and well tolerated in patients suf-
feringfromPsA.Allthepatients,atthebeginningofanti-TNF
treatment, exhibited normal liver function and a negative
viralload(<200IU/mL)duetoaresolvedviraldisease.These
conditions seem to be necessary to begin safe treatment with
anti-TNF. However, other authors reported cases of reactiva-
tion in patients with the same characteristics.
Todate,thereisnocertaintyabouttheriskofreactivation,
but, according to our findings, the relative safety of anti-TNF
and the lack of direct hepatotoxicity encourage its use in PsA
patientsresistantorintoleranttoconventionalDMARDsand
with occult or inactive viral disease. The limitations of our
study concern the small number of patients which require
studies on larger groups of patients.
Our results, however, confirm the efficacy and safety of
adalimumab, administered for long periods, in patients with
PsA and past HBV infection.4 Clinical and Developmental Immunology
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